Navigation Links
Pharmasset Joins Russell 3000 Index
Date:7/1/2008

PRINCETON, N.J., July 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) joined the broad-market Russell 3000(R) Index when Russell Investments reconstituted its equity indexes on June 27.

Pharmasset's membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000(R) Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers for index funds and as benchmarks for both passive and active investment strategies currently applied to $4.4 trillion in assets.

"We are pleased to be included in these indexes only one year after our stock became publicly traded," stated Kurt Leutzinger, Pharmasset's Chief Financial Officer. "We feel fortunate that our stock price has grown 117% since the IPO in an otherwise difficult market."

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, is in a 4-week Phase 1 clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration w
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
2. Pharmasset Selected to Join the NASDAQ Biotechnology Index
3. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
4. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
5. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
6. Pharmasset Receives $10 Million of Working Capital
7. Pharmasset Appoints Herbert J. Conrad as a Director
8. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
9. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
10. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
11. Pharmasset Reports Fiscal Year End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ... development and commercialization of a once-daily, oral therapy for ... announced financial results for the period ended June 30, ... , Reported cash and cash equivalents totaling $37.4 million ... 31, 2013.  , Reported a net loss of ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... equipment, trained personnel, and detection dogs to safeguard ... A revolutionary new electronic chip with nano-sized chemical ... easier. , The groundbreaking nanotechnology-inspired sensor, devised by ... School of Chemistry and Center for Nanoscience and ... picks up the scent of explosives molecules better ...
(Date:7/24/2014)... DUBLIN , July 24, 2014 ... the "Global Cell Culture Market 2014-2018" report ... Cell culture is the in vitro ... such as research, cell studies, and biopharmaceutical production. Cell ... vaccine production. Cell culture instruments and cell culture consumables ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6ORNL study reveals new characteristics of complex oxide surfaces 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2
... , , , ... company Viral Genetics (Pink Sheets: VRAL) has formed a wholly ... advance a technology developed by University of Colorado Professor M. ... blocking a tumor cell,s ability to generate energy from glucose ...
... SALEM, N.H., Aug. 7 ALPCO Diagnostics has introduced a ... I SA kit that facilitates the testing process ... other methods for determining mouse HMW adiponectin and was first introduced in ... Tsukuba Research Institute in the journal Clinica Chimica Acta in February 2009. ...
... , RANCHO CORDOVA, Calif., Aug. 6 ... supplier of innovative products for processing and storing adult stem cells, ... of SpineSmith, LLC, related to the Company,s bone marrow products, MXP(TM) ... leading distributor of orthopedic products, based in Texas. , ...
Cached Biology Technology:Viral Genetics Creates Subsidiary to Develop Cancer Therapy 2Viral Genetics Creates Subsidiary to Develop Cancer Therapy 3Viral Genetics Creates Subsidiary to Develop Cancer Therapy 4ALPCO Introduces a Mouse HMW and Total Adiponectin ELISA 2ThermoGenesis Announces Expanded Collaboration With Celling Technologies 2ThermoGenesis Announces Expanded Collaboration With Celling Technologies 3ThermoGenesis Announces Expanded Collaboration With Celling Technologies 4
(Date:7/27/2014)... from over 18,000 patients, scientists have identified more ... Parkinson,s disease, including six that had not been ... Genetics , was partially funded by the National ... working in NIH laboratories. , "Unraveling the genetic ... multiple mechanisms involved in this complex disease, and ...
(Date:7/25/2014)... WASHINGTON (July 24, 2014)The link between autism and ... the puzzle of the disease, and is largely ... Foundation Autism Research Initiative (SFARI), George Washington University ... to offer truly integrative and in-depth answers to ... research. , LaMantia, professor of pharmacology and ...
(Date:7/25/2014)... opened the way for the development of new lines of ... barley production is second only to wheat with 7-8 million ... important diseases of barley. , Senior Research Scientist Dr Alan ... on the cell walls of barley plants that block the ... by the ARC Centre of Excellence in Plant Cell Walls ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2GW researcher receives grant to answer the how and why of autism during development 2New hope for powdery mildew resistant barley 2
... a way, nanotubes are nature’s smallest candles. , These tiny ... small that it takes about 100,000 laid side-by-side to span ... five years, scientists have discovered that some individual nanotubes are ... light. Some glow brightly. Others glow dimly. Some glow in ...
... specialists associated with the Neuroscience Institute at the ... the ability to incorporate—in real time—two high-tech imaging ... functional abilities of patients who undergo brain surgery. ... UC colleagues are among the first in the ...
... team has discovered a gene that, when mutated, causes one ... Scientists at the University of Leeds, working in collaboration with ... which is essential to photoreceptors in the eye, the cells ... to be linked to Leber’s congenital amaurosis (LCA), comes at ...
Cached Biology News:Brightening prospects of using fluorescent nanotubes in medical applications 2Brightening prospects of using fluorescent nanotubes in medical applications 3Dual-imaging technique useful before -- and during -- brain surgery 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 2'Lucky 13' as new gene discovery offers further hope for childhood blindness 3
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
WIF-1 (N-20)...
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Biology Products: